Background: Patients' participation in treatment and care is considered to increase their safety and well-being. There is a lack of knowledge about what participation means for the patients and how it can be supported in breast cancer care. A prerequisite for patients' participation is their knowledge. Changing perspective, from patients' information needs to their learning, can increase our understanding about how participation can be facilitated. The purpose of this study was to explore patients' experiences of learning, understanding and participation in their breast cancer care. Methods: Sixteen patients with breast cancer were interviewed. The interviews were analyzed according to abductive content analysis taking the perspective from learning theories.
. The second part explores patient participation. The concept of patient participation was defined differently by different patients and there was uncertainty about its meaning. The patients' understanding of their disease, treatment and care affected their participation. A prerequisite for participation was the respectful treatment from health care staff contributing to a feeling of being "seen" as a human being. The patients' wishes varied as did their needs to participate in treatment decisions. Participation also meant a continuous struggle to manage self-care during a long period of time and access to health care is needed to support patients. College of Nursing, Ajou University, Suwon, Republic of Korea Background: Peripheral parenteral nutrition is one of the easiest ways to provide nutrition for patients who have difficulty with enteral nutrition. But, on the other hand it is attended with danger such as, phlebitis. The purpose of this study was to investigate incidence of phlebitis and its risk factors in patients with peripheral parenteral nutrition administration. Methods: Prospective observational study was performed with 289 hospitalized adult patients with gastrointestinal diseases. The researchers evaluated peripheral venous catheter that administered peripheral parenteral nutrition until their removal and investigated the incidence of phlebitis using phlebitis scale of Infusion Nurses Society (2016). Logistic regression model was used to identify risk factors involved with occurrence of phlebitis. The statistical significance limits were set at p < 0.05. Results: The incidence of phlebitis was 37.0% (107 cases). Among them, Grade I was 24.6% (71 cases), Grade II was 12.4% (36 cases) and Grade III and IV did not occur. Platelet count (OR 2.13, CI 1.07-4.26, p¼.032), nutrition infusion rate (OR 0.36, p¼.012) and infusion period (OR 1.02, CI 1.00-1.03, p¼.033) had statistically significance with phlebitis occurrence. Conclusions: Using peripheral parenteral nutrition must be carefully reconsidered for patients with risk factors of phlebitis. In using peripheral parenteral nutrition, adjusting infusion rate deserves to be considered with care. Moreover, in case of extension of peripheral parenteral nutrition therapy, medical team must regards using another way such as middle line or central line for nutrition therapy in a serious light. Background: Advanced Therapy Medicinal Products (ATMPs) such as CD 19 chimeric antigen receptor (CAR) therapies offer unprecedented promise for long term remission and even cure in pre-treated and refractory B cell malignancies. Extensive interest in new T cell engineered treatments for other malignancies has developed as a result. These complex treatments are associated with acute and potentially fatal toxicities, making patient safety paramount. CARs are often delivered on haematopoietic stem cell transplant (HSCT) units with JACIE accreditation, an internationally recognised quality system. To enhance capacity for growing numbers of ATMP trials The Christie has utilised the NIHR clinical research facility (CRF). Methods: Process mapping of the patient pathway alongside a gap analysis using JACIE standards has provided a framework to underpin the development of the CRF including: Advanced therapies team Increase in establishment Practice educator Education programme & HSCT placements JACIE quality manager to align SOPs and policies Changes to medical cover. Results: Engagement across the organisation is a priority, with a focus on safety and mitigating risk. Recruitment to key posts is underway, along with specialised staff training. Relationships are being forged and strengthened with essential specialties such as critical care and neurology. The first clinical trials are open but recruitment and use of the CRF will be carefully managed to ensure the infrastructure and processes are fit for purpose. The Christie is the lead organisation in a new consortium, iMATCH (Innovate Manchester Advanced Therapy Centre Hub) which has been awarded substantial funding from Innovate UK to scale up delivery of ATMPs and form a national network of Advanced Therapy Centres. Conclusions: CD19 specific CAR therapy is poised to become a new standard care for selected B cell malignancies. Trials of ATMPs for a range of malignancies are growing exponentially, therefore safe delivery outside of an experienced area such as HSCT is important but challenging. Creative approaches to patient care, wide collaboration and executive level support are key. While iMATCH sets the challenge to increase the number of ATMPs available it has also facilitated city wide links and a national network to find solutions to complex problems. Legal entity responsible for the study: The Christie NHS Trust. Background: The definition of patient participation is multifaceted but often reduced to solely implicate the involvement in treatment decisions. In many countries, including Sweden, there is a current shift from patient-centered care to person-centered care. This emphasizes the importance to view the patient as an equal partner and always include his or her description of their unique situation. To facilitate the participation of patients and to put their needs first, we need a wider understanding of how participation is interpreted and experienced by the patients themselves. Hence our aim was to examine this among patients with gynecological, hematological, head-neck or upper gastrointestinal cancer. Methods: A qualitative cross-sectional study was carried out. This included all patients in the Stockholm-Gotland region, diagnosed in 2016 with one of the above-mentioned cancer types. A free-text question was formulated which asked the participants to describe their experiences of participation. The question was included in a larger questionnaire study from the Regional Cancer Center and sent out to 1658 patients. Framework Analysis was used as the method to analyse and interpret the data.
Results: A total of 434 participants chose to answer the study specific free-text question and 222 of those answers were deemed to meet the aim of the study. The analytical process resulted in three themes; communication, staff attitudes and relation. Above all, the participants described how individualized information and a perceptive attitude among staff were key prerequisites for participation. Furthermore, they pointed out that absence of continuity became an obstacle for creating meaningful relations with their care provider and thus hindering their participation. Conclusions: To meet the current and future demands of individualized cancer care we need to redefine our understanding of patient participation. The emphasis, according to patients, should be on facilitating conditions to aid participation. Our understanding is that these conditions resonate the key aspects of person-centered care. Background: Deep Venous thrombosis (DVT) is one of the serious adverse events associated of bevacizumab, which is also one of the most notable complications associated with peripherally inserted central catheters (PICCs). However, there was no report about their correlation directly. The purpose of this study was to explore whether the use of PICCs increases the risk of DVT in advanced colorectal cancer and lung cancer patients with bevacizumab. Methods: From June 2011 to April 2017, patients with documented advanced colorectal cancer and lung cancer who received bevacizumab were selected from West China hospital log-out registries. The patients inserted with central venous catheters (CVCs) or ever had thrombosis were excluded. According to whether use PICCs or not, patients were divided into two groups. The incidence of DVT during the use of bevacizumab between two groups was compared. Many risk factors were also analyzed.
Results: A total of 217 patients received bevacizumab were included in this analysis. 186 patients were colorectal cancer, 31 were lung cancer. Among them, 137 patients were inserted with PICCs and 80 patients were not. 5.1% (11/217) patients had DVT during the use of bevacizumab. 4 cases had upper extremity vein thrombosis, 1 had subclavian vein hrombosis and others were lower extremity vein thrombosis. Single factor analysis revealed that patients inserted with PICCs were more likely to have DVT than others (6.6% vs. 2.5%, P ¼ 0.318), but it had no statistical difference. Background: Biological medicines has transformed cancer care drastically. As Biologics are incorporated into cancer treatment, cancer nurses play a key role in education, administration, pharmacovigilance and managing side effects of biological medicines. Expiring patents of innovator biologics creating opportunities to develop biosimilars and the number in oncology will continue to increase. The use of biosimilars will bring new challenges for cancer nurses related to education, treatment and follow-up of cancer patients. Methods: A search of PubMed, Sciencedirect and regulatory agency websites was conducted for references related to the use of biosimilars and cancer nursing. Results: To ensure optimal and safe use of biosimilars, all stakeholders incl. physicians, cancer nurses, pharmacists and patients need to understand the complexities of biosimilars and take decisions that will improve patients treatment, safety and Quality of life outcomes. As biosimilars are introduced into clinical practice, education of cancer nurses is paramount to ensure the best outcomes for patients safety. Training of nurses on new products, incl. biosimilars is often ad hoc and incomplete. As a result, cancer nurses may be unaware of the complexities and consequences of using biologics, incl. biosimilars. The knowledge gap in biosimilar medicines and switching or substitution of these medications could result in incorrect patient information, non-optimal use and adverse events which can lead to a delay in access and a decreased therapeutic gain for the patient. Conclusions: Cancer nurses have an important role in the multidisciplinary approach and treatment of patients on biologics, incl. biosimilars. They have a lead role in education and counselling during introducing and follow-up of the transition between innovator and biosimilar medicines and vice versa, to improve patient outcomes and drug safety. Additional studies on biosimilars are needed to identify current knowledge gaps and educational needs of cancer nurses across Europe. Education about biosimilars is critical for successful incorporation in to oncology practice. A deeper understanding is needed across all cancer related professions with a strong emphasis on collaboration with all stakeholders including patients. Legal entity responsible for the study: Johan De Munter. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
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Overview of an acute oncology service in a UK cancer centre M.R. Foulkes Berkshire Cancer Centre, Royal Berkshire Hospital -NHS Foundation Trust, Reading, UK Background: In the UK there has been increasing emphasis on the ability to review oncology patients who are admitted as an emergency. Two reports, NCEPOD report into systemic Anti-Cancer Therapy: For better, for worse? (2008) and the NPSA Report 'Patient safety risks of incorrect dosing of oral anti-cancer medicines ' (2008) identified shortcomings in the manner in which patients presenting to emergency departments following systemic anti-cancer treatmentrs (SACT) were cared for. This had led to increased mortality, morbidity and extended lengths of stay. In addition to the above patients presenting as an emergency with Metastatic Spinal cord compression were found to have delays in urgent treatment and patients who had a cancer diagnosis following an emergency admission had poortrer outcomes than those identified in a more controlled fashion. At the Royal Berkshire NHS Foundation trust we responded to NHS England guidance by establishing an oncologist-led acute oncology service with nursing support. We have been succesful in reducing length of stay for oncology
